Table 6.

Risk of Adverse Events from Discharge Through 6 Months In Mutually-Exclusive Discharge Medication Groupings.

Adverse event	Unadjusted			Adjusted
	HR	95% CI	P Value	HR	95% CI	P Value
Any adverse event
Warfarin and aspirin	Reference
Warfarin	0.902	0.795–1.024	0.111	0.814	0.712–0.931	0.003
DOAC and aspirin	0.928	0.831–1.037	0.187	1.048	0.910–1.206	0.519
DOAC	0.826	0.719–0.949	0.007	0.863	0.730–1.021	0.085
DAPT (P2Y12 and aspirin)	1.017	0.836–1.236	0.868	0.979	0.791–1.212	0.847
Any major adverse event
Warfarin and aspirin	Reference
Warfarin	0.915	0.807–1.037	0.164	0.840	0.737–0.958	0.010
DOAC and aspirin	0.918	0.823–1.023	0.121	1.098	0.956–1.260	0.187
DOAC	0.844	0.736–0.969	0.016	0.918	0.777–1.084	0.314
DAPT (P2Y12 and aspirin)	1.018	0.843–1.229	0.854	0.834	0.679–1.025	0.085
Any readmission
Warfarin and aspirin	Reference
Warfarin	1.064	0.957–1.183	0.251	1.081	0.966–1.210	0.175
DOAC and aspirin	1.105	1.009–1.211	0.032	1.066	0.944–1.205	0.303
DOAC	1.155	1.030–1.295	0.014	1.146	0.994–1.321	0.061
DAPT (P2Y12 and aspirin)	1.067	0.906–1.257	0.435	1.061	0.887–1.269	0.517
Any stroke or TIA
Warfarin and aspirin	Reference
Warfarin	1.108	0.807–1.521	0.527	1.129	0.801–1.591	0.489
DOAC and aspirin	1.298	1.003–1.680	0.048	1.051	0.751–1.470	0.772
DOAC	1.241	0.903–1.705	0.183	0.920	0.618–1.369	0.680
DAPT (P2Y12 and aspirin)	1.230	0.778–1.942	0.376	1.086	0.654–1.803	0.750

Abbreviations as in Table 1.